FLNA vs GANX

Filana Therapeutics, Inc. vs Gain Therapeutics, Inc. — Valuation Comparison 2026

FLNA

Biotechnology
Filana Therapeutics, Inc.
Quality
4.5
out of 10
Value Trap
18
SAFE
Price
$1.55
Last close
Models
8/13
Active
VS

GANX

Biotechnology
Gain Therapeutics, Inc.
Quality
4.3
out of 10
Value Trap
32
LOW
Price
$2.02
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType FLNA Fair ValueFLNA Upside GANX Fair ValueGANX Upside
Bayesian DCF Intrinsic $1.40 -9.9% $0.75 -63.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.15 -89.9% $0.47 -76.7%
Dynamic NAV Asset-Based $0.98 -36.6% $0.64 -68.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for FLNA vs GANX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

FLNA vs GANX — Which Stock Is More Undervalued?

FLNA scores higher with a 4.5/10 quality rating vs GANX's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Filana Therapeutics, Inc. (FLNA) and Gain Therapeutics, Inc. (GANX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

FLNA currently trades at $1.55 with a QOC of 4.5/10, while GANX trades at $2.02 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).